Immunovant (IMVT) director receives 13,880 RSUs and 7,061 options
Rhea-AI Filing Summary
Immunovant, Inc. director Robert Graham Susman reported equity awards consisting of new stock options and restricted stock units (RSUs). He was granted options for 7,061 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036. The shares underlying these options will vest on April 1, 2027, subject to his continuous service. He also received 13,880 RSUs, each representing one share of common stock, which will vest in full on April 1, 2027 under the same service condition. The filing notes he may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Following the RSU grant, he directly owns 38,896 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 13,880 shares
Net Buy
2 txns
Insider
Susman Robert Graham
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 7,061 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 13,880 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 7,061 shares (Direct);
Common Stock — 38,896 shares (Direct)
Footnotes (2)
- F1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
- F2. These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.
Key Figures
RSU grant: 13,880 units
Option grant size: 7,061 shares
Option exercise price: $24.61 per share
+3 more
6 metrics
RSU grant
13,880 units
Restricted stock units vesting April 1, 2027
Option grant size
7,061 shares
Stock options granted April 7, 2026
Option exercise price
$24.61 per share
Strike price for new stock options
Option expiration
April 7, 2036
Expiration date of granted stock options
Shares held after grant
38,896 shares
Common stock directly owned after RSU award
Options held after grant
7,061 options
Total options following transaction
Key Terms
restricted stock units, 2019 Equity Incentive Plan, Rule 409A, continuous service, +1 more
5 terms
restricted stock units financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2019 Equity Incentive Plan financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan")"
Rule 409A financial
"The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A"
continuous service financial
"The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer"
stock options financial
"These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity awards did Immunovant (IMVT) director Robert Graham Susman receive?
He received 13,880 restricted stock units and stock options for 7,061 shares of Immunovant common stock. Both awards were granted at no cash cost as compensation under the company’s 2019 Equity Incentive Plan, subject to future vesting conditions tied to his continued service.
When do Robert Graham Susman’s new Immunovant (IMVT) RSUs and options vest?
Both the 13,880 RSUs and the options for 7,061 underlying shares are scheduled to vest on April 1, 2027. Vesting is conditioned on his continuous service to Immunovant through that date, meaning he must remain in service for the awards to become fully earned.
What is the exercise price and expiration date of Susman’s Immunovant (IMVT) stock options?
The granted stock options have an exercise price of $24.61 per share and expire on April 7, 2036. He can only exercise these options after vesting on April 1, 2027, and before the expiration date, subject to the plan’s terms and any applicable restrictions.
Can Robert Graham Susman defer settlement of his Immunovant (IMVT) RSUs?
Yes. The filing states he may elect to defer settlement of the RSUs when they vest, subject to the requirements of Rule 409A. This means receipt of the underlying common shares can be postponed in accordance with applicable deferred compensation rules and the plan’s provisions.
Under what plan were Robert Graham Susman’s Immunovant (IMVT) awards granted?
Both the RSUs and stock options were granted under Immunovant’s 2019 Equity Incentive Plan. This plan governs the terms of equity compensation, including vesting schedules, exercise conditions, and any potential deferral of settlement allowed for participants such as company directors.